89 related articles for article (PubMed ID: 21315276)
1. Automated preparation of Re-188 lipiodol for the treatment of hepatocellular carcinoma.
Uccelli L; Pasquali M; Boschi A; Giganti M; Duatti A
Nucl Med Biol; 2011 Feb; 38(2):207-13. PubMed ID: 21315276
[TBL] [Abstract][Full Text] [Related]
2. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection.
Luo TY; Hsieh BT; Wang SJ; Lin WY; Lee TW; Shen LH; Su MJ
Nucl Med Biol; 2004 Jul; 31(5):671-7. PubMed ID: 15219287
[TBL] [Abstract][Full Text] [Related]
3. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
[TBL] [Abstract][Full Text] [Related]
4. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.
Boschi A; Uccelli L; Duatti A; Colamussi P; Cittanti C; Filice A; Rose AH; Martindale AA; Claringbold PG; Kearney D; Galeotti R; Turner JH; Giganti M
Nucl Med Commun; 2004 Jul; 25(7):691-9. PubMed ID: 15208496
[TBL] [Abstract][Full Text] [Related]
5. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model.
Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC
J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730
[TBL] [Abstract][Full Text] [Related]
6. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
[TBL] [Abstract][Full Text] [Related]
7. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.
Lambert B; Bacher K; De Keukeleire K; Smeets P; Colle I; Jeong JM; Thierens H; Troisi R; De Vos F; Van de Wiele C
J Nucl Med; 2005 Aug; 46(8):1326-32. PubMed ID: 16085590
[TBL] [Abstract][Full Text] [Related]
8. 131-iodine Lipiodol therapy in hepatocellular carcinoma.
Raoul JL; Boucher E; Roland V; Garin E
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):348-55. PubMed ID: 19521315
[TBL] [Abstract][Full Text] [Related]
9. Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs.
Garin E; Noiret N; Malbert C; Lepareur N; Roucoux A; Caulet-Maugendre S; Moisan A; Lecloirec J; Herry JY; Bourguet P
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):542-6. PubMed ID: 14691613
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model.
Tang IC; Luo TY; Liu SW; Chan SH; Kung HC; Peng CL; Lin WY; Chang Y; Lin WJ
Nucl Med Biol; 2011 Oct; 38(7):1043-52. PubMed ID: 21831647
[TBL] [Abstract][Full Text] [Related]
11. Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer.
Jeong JM; Kim YJ; Lee YS; Ko JI; Son M; Lee DS; Chung JK; Park JH; Lee MC
Nucl Med Biol; 2001 Feb; 28(2):197-204. PubMed ID: 11295430
[TBL] [Abstract][Full Text] [Related]
12. Effect of a 188 Re-SSS lipiodol/131I-lipiodol mixture, 188 Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma.
Garin E; Rakotonirina H; Lejeune F; Denizot B; Roux J; Noiret N; Mesbah H; Herry JY; Bourguet P; Lejeune JJ
Nucl Med Commun; 2006 Apr; 27(4):363-9. PubMed ID: 16531923
[TBL] [Abstract][Full Text] [Related]
13. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.
Das T; Chakraborty S; Sarma HD; Venkatesh M; Banerjee S
Nucl Med Commun; 2009 May; 30(5):362-7. PubMed ID: 19282794
[TBL] [Abstract][Full Text] [Related]
14. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.
Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675
[TBL] [Abstract][Full Text] [Related]
15. A report on the implementation aspects of the International Atomic Energy Agency's first doctoral coordinated research project, "Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry".
Padhy AK; Dondi M
Semin Nucl Med; 2008 Mar; 38(2):S5-12. PubMed ID: 18243843
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma.
Huang PW; Tsai SC; Luo TY; Kao CH; Lin WY
Ann Nucl Med; 2013 Jul; 27(6):532-7. PubMed ID: 23479326
[TBL] [Abstract][Full Text] [Related]
17. Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol.
Lee YS; Jeong JM; Kim YJ; Chang YS; Lee HJ; Son M; Lee JW; Yoon HS; Kang WJ; Lee DS; Chung JK; Lee MC; Suh YG
Appl Radiat Isot; 2007 Jan; 65(1):64-9. PubMed ID: 17010628
[TBL] [Abstract][Full Text] [Related]
18. Reduction of β-radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatment.
Lepareur N; Laffont S; Ardisson V; Noiret N; Garin E
Nucl Med Commun; 2012 Feb; 33(2):205-8. PubMed ID: 22124362
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the potential of (188)Re-ECD/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment.
Luo TY; Shih YH; Chen CY; Tang IC; Wu YL; Kung HC; Lin WJ; Lin XZ
Cancer Biother Radiopharm; 2009 Oct; 24(5):535-41. PubMed ID: 19877883
[TBL] [Abstract][Full Text] [Related]
20. Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases.
Liepe K; Kotzerke J; Lambert B
J Nucl Med; 2005 Aug; 46(8):1407-8; author reply 1407-8. PubMed ID: 16085601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
